← Back to medicines
Medicine Image
OTC

Felbo 0.03

Incepta Pharmaceuticals Ltd. · Topical Gel

Generic

Felbinac

Strength0.03
Unit Price
300

/ 30 gm tube

Order Now

Medicine Description

Detailed scientific information regarding the indications, dosage, potential side effects, and guidelines for use during pregnancy of Felbo or the Felbinac group is provided below. Always consult a specialist physician before taking any medication.

Felbo 0.03 | INDICATIONS AND USES

Felbinac is indicated for the relief of symptoms associated with painful inflammatory conditions of the musculo-skeletal system such as:

Soft tissue traumas (sprains, strains and contusions).
Extra-articular rheumatic or inflammatory conditions including bursitis, capsulitis, frozen shoulder, myalgia, tendonitis, tenosynovitis and tennis elbow.
For the relief of pain and stiffness of rheumatic or non-serious arthritic conditions (i.e. common arthritis).


Felbo 0.03 | PHARMACOLOGY

The primary mechanism of action of Felbinac revolves around its ability to inhibit the cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. These enzymes play a pivotal role in the biosynthesis of prostaglandins, which are lipid compounds that have several crucial functions in the body, including mediating inflammation, pain, and fever. By inhibiting COX enzymes, Felbinac effectively reduces the production of prostaglandins. This reduction attenuates the inflammatory response and provides relief from pain.


Felbo 0.03 | DOSAGE & ADMINISTRATION

Rub 1 gm gel lightly into the affected area 2 to 4 times a day. If symptoms do not resolve, the patient should be reviewed to assess whether continued treatment is appropriate. The total dose should not exceed 25 g a day, regardless of the number of affected areas. Treatment should not be extended beyond 6 weeks.Elderly: No special dosage recommendations are made for elderly patients, however, NSAIDs should be used with particular caution in elderly patients who are more prone to adverse events. The lowest dose compatible with adequate safe clinical control should be employed. Paediatric population: There is insufficient information regarding the safety and efficacy of this medicine in children. It is not recommended for children under 18 yrs.Method of administration: Topical to affected area: Hands should be washed following application of Felbinac 3% Gel, unless they are the treatment sites.


Felbo 0.03 | DRUG INTERACTIONS

Felbinac is highly protein bound, however serum levels following topical application are extremely low, therefore clinical drug interactions are unlikely.


Felbo 0.03 | USE DURING PREGNANCY AND LACTATION

Felbinac is suspected to cause serious birth defects when administered during pregnancy. Traxam 3% w/w Gel is contraindicated in pregnancy. As with other non-steroidal anti-inflammatory agents, which inhibit prostaglandin synthesis, dystocia and delayed parturition were observed when felbinac was administered subcutaneously in animal studies. Traxam 3% w/w Gel should not be used during breast-feeding. Traxam 3% w/w Gel is contraindicated during breastfeeding.


Felbo 0.03 | PRECAUTIONS & WARNINGS

Undesirable effects may be reduced by using the minimum effective dose for the shortest possible duration. Concomitant long term use of NSAIDs long term, should undergo regular medical supervision to monitor for adverse events. Avoid contact with eyes and mucus membrane.
The total dose of product should not exceed 25g daily.
If there is no improvement or the condition is aggravated, the doctor should be consulted. Although the systemic effects should be low, the drug should be used with caution in patients with renal, cardiac or hepatic impairment, history of peptic ulceration, inflammatory bowel disease or bleeding diathesis.
Elderly patients are particularly susceptible to the adverse effects of NSAIDs. Prolonged use of NSAIDs in the elderly is not recommended. Where prolonged therapy is required, patients should be reviewed regularly.
As NSAIDs can interfere with platelet function, they should be used with caution in patients with intracranial haemorrhage and
bleeding diathesis. It should only be used on non-diseased skin.
To avoid the possibility of photosensitivity, patients should be advised against excessive exposure to sunlight of treated areas.
This medicine contains 300 mg of alcohol (ethanol) in each 1 g. which is equivalent to 300 mg/g (30%w/w). It may cause burning sensation on damaged skin.


Felbo 0.03 | THERAPEUTIC CLASS

Topical anti-inflammatory preparations


Felbo 0.03 | STORAGE CONDITIONS

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

⚠ Disclaimer

The information provided on All Samadhan is intended for general informational purposes only and is prepared based on our best practices. It is not a substitute for professional medical advice, diagnosis, or treatment. While we strive to keep the information accurate and up to date, we do not guarantee its completeness or accuracy. The absence of specific information or warnings about any medicine or service should not be considered as an assurance or endorsement by All Samadhan. All Samadhan shall not be held responsible for any consequences arising from the use of this information. We strongly recommend consulting a qualified healthcare professional or physician for any medical concerns, questions, or clarifications.All Samadhan is a digital healthcare software platform operated by MS Genius Experts. We provide technology solutions for pharmacies and healthcare providers; we are not a direct seller or dispenser of prescription medicines

allsomadhan logo

N:B-All Samadhan is a digital healthcare software platform operated by MS Genius Experts. We provide technology solutions for pharmacies and healthcare providers; we are not a direct seller or dispenser of prescription medicines"

Copyright © All Samadhan - Operated by M/S. Genius Experts | All Rights Reserved

DBID

Registration ID: 176322642

Trade License: TRAD/DNCC/040904/2023

Payment Methods
google play storeapple store
Chat with us